title: Is it the primetime for endoglin (CD105) in the clinical setting?
authors.forename: Michele
authors.initials: M
authors.lastname: Maio
authors.forename: Maresa
authors.initials: M
authors.lastname: Altomonte
authors.forename: Ester
authors.initials: E
authors.lastname: Fonsatti
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D000071063:Endoglin; D006801:Humans; D009389:Neovascularization, Pathologic; D011956:Receptors, Cell Surface / Q000276:immunology*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface